Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Bristol-Myers Eyes Antibody Start-up
by Lisa M. Jarvis
November 3, 2014
| A version of this story appeared in
Volume 92, Issue 44
Bristol-Myers Squibb has paid $50 million for an option to acquire F-star Alpha, a Cambridge, England-based biotech developing bispecific antibodies to treat cancer. The deal includes FS102, which binds to a unique site on HER2, a protein implicated in breast and gastric cancers. BMS will pay for and conduct clinical trials of FS102, which is poised to enter Phase I studies, and can acquire F-star Alpha if the molecule reaches Phase IIb studies. F-star Alpha investors could net up to $475 million if BMS acquires the company and FS102 makes it all the way to the market.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter